Philip Goulder Selected Research

Philip Goulder Research Topics

Disease

32	Infections 05/2024 - 07/2005
15	HIV Infections (HIV Infection) 01/2024 - 01/2007
10	COVID-19 05/2024 - 06/2020
10	Disease Progression 01/2020 - 07/2010
5	Viremia 01/2023 - 01/2007
4	Acquired Immunodeficiency Syndrome (AIDS) 11/2020 - 07/2010
2	Hepatitis C 01/2023 - 05/2006
2	Virus Diseases (Viral Diseases) 01/2023 - 01/2007
2	Human Influenza (Influenza) 01/2023 - 01/2021
2	Shock 01/2018 - 01/2018
1	Hepatitis D 01/2023
1	Inflammation (Inflammations) 01/2022
1	Measles 01/2022
1	Neoplasms (Cancer) 01/2022
1	Breakthrough Infections 01/2022
1	Critical Illness (Critically Ill) 01/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2020
1	Malnutrition (Nutritional Deficiencies) 01/2018
1	Persistent Infection 01/2018
1	Coinfection 01/2015
1	Crohn Disease (Crohn's Disease) 04/2013
1	Communicable Diseases (Infectious Diseases) 01/2011

Drug/Important Bio-Agent (IBA)

12	VaccinesIBA 01/2023 - 01/2007
10	EpitopesIBA 01/2018 - 01/2007
8	HLA-B Antigens (HLA-B)IBA 01/2018 - 04/2009
7	Antiviral Agents (Antivirals)IBA 01/2023 - 09/2014
6	AntibodiesIBA 01/2024 - 01/2021
6	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2007
5	HLA-B57 antigenIBA 01/2018 - 04/2009
4	Peptides (Polypeptides)IBA 11/2020 - 02/2015
3	N-methyl-valyl-amiclenomycin (BA 2)IBA 05/2024 - 01/2022
3	BNT162 VaccineIBA 01/2024 - 01/2022
3	Broadly Neutralizing AntibodiesIBA 01/2024 - 01/2018
3	AntigensIBA 01/2023 - 05/2006
3	InterferonsIBA 01/2023 - 11/2020
2	mRNA VaccinesIBA 01/2024 - 01/2022
2	Messenger RNA (mRNA)IBA 01/2023 - 07/2015
2	Immunoglobulin G (IgG)IBA 01/2023 - 01/2022
2	Immunodominant EpitopesIBA 06/2020 - 06/2015
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 06/2020 - 01/2011
2	HLA-C Antigens (HLA-C)IBA 01/2019 - 04/2013
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2016 - 02/2015
2	Human Immunodeficiency Virus ProteinsIBA 04/2009 - 01/2007
1	Monoclonal AntibodiesIBA 05/2024
1	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2023
1	COVID-19 VaccinesIBA 01/2022
1	Interferon Type IIBA 01/2022
1	N-(2-cyanoethylene)urea (BA 1)IBA 01/2022
1	EnzymesIBA 01/2022
1	Viral AntigensIBA 01/2021
1	ChAdOx1 nCoV-19IBA 01/2021
1	Blood Proteins (Serum Proteins)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Neutralizing AntibodiesIBA 01/2021
1	tapasinIBA 11/2020
1	HLA-B*52:01 antigenIBA 01/2020
1	Interleukin-10 (Interleukin 10)IBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Indicators and Reagents (Reagents)IBA 01/2018
1	HIV AntigensIBA 01/2018
1	Amino Acids FDA Link 01/2018
1	nef Gene Products (nef Gene Product)IBA 01/2018
1	Glycoproteins (Glycoprotein)IBA 01/2018
1	Rilpivirine (TMC-278)IBA 10/2017
1	CytokinesIBA 02/2016
1	HLA-A Antigens (HLA-A)IBA 06/2015
1	HLA-B35 Antigen (HLA B35 Antigen)IBA 07/2014
1	HLA-B*07 antigenIBA 05/2014
1	HLA-A*68 antigenIBA 07/2013
1	Biomarkers (Surrogate Marker)IBA 09/2009
1	Nevirapine (Viramune)FDA Link 06/2007
1	AIDS VaccinesIBA 01/2007
1	PerforinIBA 07/2005

Therapy/Procedure

11	Therapeutics 12/2021 - 07/2007
6	Art Therapy 01/2023 - 06/2007
2	Highly Active Antiretroviral Therapy (HAART) 12/2021 - 05/2020